Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Sympathetic activity" patented technology

What is Sympathetic Activity. 1. The activity of nervous system that takes over where an immediate and effective response is required. The sympathetic nervous system works alongside the parasympathetic nervous system and is known as the involuntary system because the actions caused by it are not consciously executed.

Devices And Methods For Detection And Treatment Of The Aorticorenal Ganglion

ActiveUS20140330267A1Limiting endothelial tissue damageDeep modificationSpinal electrodesTomographyRenal pelvisBlood vessel
Devices and methods that regulate the innervation of the kidney by detection and modification of the aorticorenal ganglion. Devices for percutaneous detection and treatment of the aorticorenal ganglion via a blood vessel to modify renal sympathetic activity.
Owner:HALCYON MEDICAL INC

Use of Antagonists of Hepatic Sympathetic Nerve Activity

The present invention provides pharmaceutical compositions comprising antagonists of hepatic sympathetic activity and methods for using said pharmaceutical compositions for treatment of hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridaemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, renal failure, sexual dysfunction, chronic stress, and anxiety.
Owner:UNIVERSITY OF MANITOBA

Pharmaceutical formulation for treating cardiovascular diseases

The invention discloses a pharmaceutical formulation for treating cardiovascular diseases. The pharmaceutical formulation comprises chondroitin sulfate, notopterygium root, cornua cervi pantotrichum, honeysuckle, radix scrophulariae, sucrose octaacetate, orange essence, agastache rugosus essence, betacyclodextrin, longstamen onion bulb, hawthorn, corydalis tuber, radix pueraiae, red flower, peach kernel, ginkgo leaf, selfheal, pine needle, sophora japonica, chrysanthemum indicum, pig's bile, dried white peony root, H2 receptor antagonist and beta 1 receptor antagonist. The pharmaceutical formulation has the advantages that the beta 1 receptor antagonist and the H2 receptor antagonist are combined with the traditional Chinese medicine to prepare new compound drug preparation, the preparation has a sympathetic activity resisting effect in vivo, and the effect directions are consistent; due to the fact that effect targets of the beta 1 receptor antagonist and the H2 receptor antagonist are different, effective synergy is achieved, that is to say, the use amount of the beta 1 receptor antagonist and the H2 receptor antagonist can be reduced, toxic and side effect occurrence rate can be lowered, curative effect can be brought into play through various channels, effective therapeutic effects on the cardiovascular diseases including coronary heart diseases, arrhythmia, hypertension and congestive heart failure can be achieved, and the pharmaceutical formulation is worthy of popularization and application.
Owner:何功浩

Transcutaneous spinal cord stimulation for treatment of psychiatric disorders

Methods of treating a psychiatric disorder in a subject are provided which include placing at least one anode on an area of the subject's back over the dorsal spinal cord at the level of one or more of: thoracic vertebra 7 (T7), 8 (T8), 9 (T9), 10 (T10), 11 (T11), and 12 (T12) and lumbar vertebra 1 (L1); placing at least one cathode on an area of the subject's back which is generally rostral with reference to the anode; connecting the anode and the cathode to at least one source of direct and / or alternating electrical current; delivering direct current to the anode for a treatment period of time, the treatment period of time defining a tsDCS and / or tsACS treatment session, thereby modulating spinal input to the brain of the subject, decreasing sympathetic activity and reducing one or more symptoms and / or comorbidities associated with the psychiatric disorder.
Owner:UNIVERSITY OF CINCINNATI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products